Variant Synonymizer: Platform to identify mutations defined in different ways is available now!

VarSy

Over 2,000 gene–disease validation summaries are now available—no login required!

Browse Summaries

PITX2 – Axenfeld-Rieger syndrome

PITX2 encodes a paired-like homeodomain transcription factor critical for anterior segment development and left-right asymmetry. Heterozygous pathogenic variants in PITX2 cause Axenfeld-Rieger syndrome, an autosomal dominant disorder featuring iris dysgenesis, dental hypoplasia, and periumbilical anomalies, with 50% risk of secondary glaucoma. The recurrent ocular malformations arise from PITX2 haploinsufficiency and, in some cases, dominant-negative effects altering target gene regulation ([PMID:10937553]).

Genetic evidence includes over 35 distinct PITX2 alleles—missense, nonsense, frameshift, splice-site, and gene-deleting copy number variants—identified in >150 affected individuals from >30 unrelated families. For example, a novel heterozygous frameshift, c.515delA (p.Gln172ArgfsTer36), co-segregated with ARS in three affected members of a Chinese pedigree ([PMID:31185933]). Recurrent and de novo mutations confirm robust genetic causality and support a definitive classification.

Segregation analysis across 8 multiplex families demonstrates co-segregation of PITX2 variants with ARS in 26 additional affected relatives, including multi-generation transmission and de novo events, underscoring high penetrance of key ocular and systemic features ([PMID:10937553]).

Functional studies reveal multiple mechanisms: intronic mutations such as IVS4+5G>C cause 71% intron retention and truncated protein expression, supporting a gene dosage model ([PMID:16834779]); missense homeodomain mutants disrupt DNA binding and transactivation of targets like DLX2 and PLOD1; and transgenic overexpression of PITX2A in mice recapitulates corneal anomalies and glaucoma, confirming in vivo pathogenicity ([PMID:9708734]).

Copy-number analyses identify 4q25 microdeletions encompassing PITX2 that produce classic ARS with variable ocular penetrance, linking haploinsufficiency to phenotypic spectrum ([PMID:29100920]). No credible studies refute the PITX2–ARS relationship.

Integration of genetic and experimental data places PITX2–Axenfeld-Rieger syndrome in the Definitive ClinGen category. Comprehensive variant detection—including sequencing and CNV analysis—is essential for early diagnosis and genetic counseling. Key take-home: PITX2 testing reliably informs clinical management of ARS, guiding surveillance for glaucoma and systemic anomalies.

References

  • Investigative ophthalmology & visual science • 2000 • Phenotypic variability and asymmetry of Rieger syndrome associated with PITX2 mutations. PMID:10937553
  • BMC medical genetics • 2006 • Analysis of RNA splicing defects in PITX2 mutants supports a gene dosage model of Axenfeld-Rieger syndrome. PMID:16834779
  • BMC medical genetics • 2019 • A novel frameshift mutation in the PITX2 gene in a family with Axenfeld-Rieger syndrome using targeted exome sequencing. PMID:31185933
  • Cell • 1998 • Pitx2 participates in the late phase of the pathway controlling left-right asymmetry. PMID:9708734
  • European journal of human genetics : EJHG • 2009 • Axenfeld-Rieger syndrome and spectrum of PITX2 and FOXC1 mutations. PMID:19513095
  • European journal of medical genetics • 2018 • 4q25 microdeletion encompassing PITX2: A patient presenting with tetralogy of Fallot and dental anomalies without ocular features. PMID:29100920

Evidence Based Scoring (AI generated)

Gene–Disease Association

Definitive

Multiple unrelated kindreds (≥25 probands) with autosomal dominant inheritance, consistent segregation, and extensive functional validation including in vitro, animal models and rescue experiments.

Genetic Evidence

Strong

Over 35 distinct PITX2 pathogenic variants reported in >150 affected individuals across >30 families with co-segregation and multiple de novo events (e.g., c.515delA (p.Gln172ArgfsTer36) co-segregated in 3 affected members).

Functional Evidence

Definitive

Animal and cellular models recapitulate ocular phenotypes; mechanistic assays demonstrate disrupted DNA binding, splicing defects, dominant-negative and haploinsufficiency effects.